Cited by 164Bone Metabolism and DiseasesNF-κB Signaling PathwaysRheumatoid Arthritis Research and Therapies

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Open access
Xiu, Yan, Xu, Hao, Zhao, Chen, Li, Jinbo, Morita, Yoshikazu, Yao, Zhenqiang, Xing, Lianping, Boyce, Brendan F.·2014·Journal of Clinical Investigation

Abstract

The cytokines RANKL and TNF activate NF-κB signaling in osteoclast precursors (OCPs) to induce osteoclast (OC) formation. Conversely, TNF can limit OC formation through NF-κB p100, which acts as an inhibitor, and TNF receptor-associated receptor 3 (TRAF3); however, a role for TRAF3 in RANKL-mediated OC formation is unknown. We found that TRAF3 limits RANKL-induced osteoclastogenesis by suppressing canonical and noncanonical NF-κB signaling. Conditional OC-specific Traf3-KO (cKO) mice had mild osteoporosis and increased OC formation. RANKL induced TRAF3 degradation via the lysosome/autophagy system. The autophagy/lysosome inhibitor chloroquine reduced RANKL-induced OC formation and function by increasing TRAF3 expression in OCPs in vitro and in vivo. Although chloroquine had no effect on basal bone resorption, it inhibited parathyroid hormone- and ovariectomy-induced OC activation in WT, but not cKO, mice. Deletion of the transcription factor gene Relb resulted in increased TRAF3 expression in OCPs, which was associated with decreased RANKL-induced TRAF3 degradation. RelB directly increased expression of BECN1, a key autophagy regulator, by binding to its promoter. These data indicate that autophagic/lysosomal degradation of TRAF3 is an important step in RANKL-induced NF-κB activation in OCPs. Furthermore, treatments that increase TRAF3 levels in OCPs, including pharmacological inhibition of its degradation with compounds such as chloroquine, may limit bone destruction in common bone diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci66947

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Conditional deletion of TRAF3, an inhibitor of the noncanonical pathway, in osteoclast precursors resulted in increased osteoclast formation and bone resorption in mice.

    “conditional deletion of TRAF3, an inhibitor of the noncanonical pathway, in osteoclast precursors resulted in increased osteoclast formation and bone resorption in mice.171”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 72 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Xiu, Y., Xu, H., Zhao, C., Li, J., Morita, Y., Yao, Z., Xing, L., & Boyce, B. F.
Affiliations
University of Rochester Medicine (US)
Corresponding author
Boyce, Brendan F.
Venue
Journal of Clinical Investigation
Published
2013-12-09
Volume
124
Issue
1
Pages
297-310
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2103768376
Cited by
164
References
72
Citations by year
2026: 7 · 2025: 12 · 2024: 7 · 2023: 12 · 2022: 14 · 2021: 16 · 2020: 26 · 2019: 20 · 2018: 13 · 2017: 20 · 2016: 6 · 2015: 7 · 2014: 4
FWCI
2.54
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Rochester
  • Medical Center, University of Rochester
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR061307, T32AR053459, AR 43510, AR 48697, R01AR048697, R01AR063650, R01AR043510)
  • National Center for Research Resources (S10RR027340)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
chloroquine, osteoclastogenesis, TRAF3, RANKL, NF-κB signaling, autophagy, lysosomal degradation, osteoporosis, RelB, Beclin-1, osteoclast precursors, bone resorption, ovariectomy, parathyroid hormone
MeSH terms
Beclin-1, Animals, Bone Resorption, Cells, Cultured, Chloroquine, Female, Gene Expression Regulation, Lysosomes, Mice, Inbred C57BL, Osteoclasts, Osteoporosis, Promoter Regions, Genetic, Protein Binding, Mice, Knockout, TNF Receptor-Associated Factor 3, Apoptosis Regulatory Proteins, Mice, Transcription Factor RelB, RANK Ligand, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review